| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/08/2023 | 38.81% | EF Hutton | → $24 | Reiterates | → Buy |
| 01/26/2023 | 67.73% | Credit Suisse | → $29 | Initiates Coverage On | → Outperform |
| 01/19/2023 | 38.81% | JMP Securities | $25 → $24 | Maintains | Market Outperform |
| 01/11/2023 | 38.81% | EF Hutton | $28 → $24 | Maintains | Buy |
| 12/09/2022 | 44.59% | JMP Securities | $26 → $25 | Maintains | Market Outperform |
| 11/02/2022 | 67.73% | RBC Capital | $31 → $29 | Maintains | Outperform |
| 11/02/2022 | 27.24% | Morgan Stanley | $23 → $22 | Maintains | Equal-Weight |
| 11/01/2022 | 61.94% | EF Hutton | → $28 | Initiates Coverage On | → Buy |
| 10/18/2022 | 50.38% | JMP Securities | → $26 | Initiates Coverage On | → Market Outperform |
| 07/26/2022 | 85.08% | Piper Sandler | $30 → $32 | Maintains | Overweight |
| 07/15/2022 | 33.02% | Morgan Stanley | $22 → $23 | Maintains | Equal-Weight |
| 06/24/2022 | 61.94% | BMO Capital | → $28 | Initiates Coverage On | → Outperform |
| 02/18/2022 | 142.91% | HC Wainwright & Co. | $52 → $42 | Maintains | Buy |
| 11/03/2021 | 79.29% | RBC Capital | $32 → $31 | Maintains | Outperform |
| 11/03/2021 | 200.75% | HC Wainwright & Co. | $65 → $52 | Maintains | Buy |
| 11/02/2021 | 67.73% | Oppenheimer | $30 → $29 | Maintains | Outperform |
| 10/07/2021 | 61.94% | Jefferies | → $28 | Initiates Coverage On | → Buy |
| 09/20/2021 | 108.21% | Truist Securities | $37 → $36 | Maintains | Buy |
| 06/28/2021 | 73.51% | Needham | $33 → $30 | Maintains | Buy |
| 06/15/2021 | 171.83% | HC Wainwright & Co. | → $47 | Initiates Coverage On | → Buy |
| 04/19/2021 | 50.38% | Morgan Stanley | $27 → $26 | Maintains | Equal-Weight |
| 03/31/2021 | 73.51% | Credit Suisse | → $30 | Initiates Coverage On | → Outperform |
| 03/12/2021 | 102.43% | Wolfe Research | → $35 | Initiates Coverage On | → Outperform |
| 02/16/2021 | 108.21% | Piper Sandler | $33 → $36 | Maintains | Overweight |
| 12/16/2020 | 56.16% | Morgan Stanley | $29 → $27 | Maintains | Equal-Weight |
| 10/26/2020 | 56.16% | Stifel | $26 → $27 | Maintains | Hold |
| 09/22/2020 | 67.73% | Morgan Stanley | $23 → $29 | Maintains | Equal-Weight |
| 09/21/2020 | 90.86% | Piper Sandler | $30 → $33 | Maintains | Overweight |
| 09/21/2020 | 114% | Oppenheimer | $33 → $37 | Maintains | Outperform |
| 08/07/2020 | 33.02% | Morgan Stanley | $22 → $23 | Maintains | Equal-Weight |
| 07/15/2020 | 27.24% | Morgan Stanley | $21 → $22 | Maintains | Equal-Weight |
| 06/01/2020 | 85.08% | Oppenheimer | $28 → $32 | Maintains | Outperform |
| 05/14/2020 | 131.35% | SunTrust Robinson Humphrey | $35 → $40 | Maintains | Buy |
| 05/06/2020 | 56.16% | BMO Capital | $20 → $27 | Maintains | Market Perform |
| 05/06/2020 | 21.46% | Morgan Stanley | $20 → $21 | Maintains | Equal-Weight |
| 04/21/2020 | 61.94% | Oppenheimer | $25 → $28 | Maintains | Outperform |
| 04/20/2020 | 90.86% | Needham | $28 → $33 | Maintains | Buy |
| 03/04/2020 | 50.38% | Barclays | → $26 | Initiates Coverage On | → Overweight |
| 02/26/2020 | 33.02% | Stifel | $21 → $23 | Maintains | Hold |
| 02/26/2020 | 15.67% | BMO Capital | $19 → $20 | Maintains | Market Perform |
| 01/13/2020 | 79.29% | SunTrust Robinson Humphrey | → $31 | Initiates Coverage On | → Buy |
| 01/13/2020 | 21.46% | B of A Securities | $22 → $21 | Reiterates | → Buy |
| 10/15/2019 | 44.59% | Guggenheim | $33 → $25 | Maintains | Buy |
| 10/08/2019 | 9.89% | BMO Capital | $23 → $19 | Maintains | Market Perform |
| 08/01/2019 | 33.02% | Stifel | $22 → $23 | Maintains | Hold |
| 03/18/2019 | — | Morgan Stanley | Upgrades | Underweight → Equal-Weight | |
| 02/22/2019 | 33.02% | BMO Capital | → $23 | Initiates Coverage On | → Market Perform |
| 09/17/2018 | 27.24% | Goldman Sachs | → $22 | Initiates Coverage On | → Neutral |
| 09/10/2018 | 9.89% | Morgan Stanley | → $19 | Initiates Coverage On | → Underweight |
| 08/01/2018 | 44.59% | Stifel | $29 → $25 | Maintains | Hold |
| 05/03/2018 | 67.73% | Stifel | $30 → $29 | Maintains | Hold |
| 02/27/2018 | 73.51% | Stifel | $29 → $30 | Maintains | Hold |
| 02/27/2018 | — | Oppenheimer | Upgrades | Perform → Outperform |
What is the target price for Exelixis (EXEL)?
The latest price target for Exelixis (NASDAQ: EXEL) was reported by EF Hutton on February 8, 2023. The analyst firm set a price target for $24.00 expecting EXEL to rise to within 12 months (a possible 38.81% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Exelixis (EXEL)?
The latest analyst rating for Exelixis (NASDAQ: EXEL) was provided by EF Hutton, and Exelixis reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Exelixis (EXEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exelixis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exelixis was filed on February 8, 2023 so you should expect the next rating to be made available sometime around February 8, 2024.
Is the Analyst Rating Exelixis (EXEL) correct?
While ratings are subjective and will change, the latest Exelixis (EXEL) rating was a reiterated with a price target of $0.00 to $24.00. The current price Exelixis (EXEL) is trading at is $17.29, which is within the analyst's predicted range.